# Defencath (heparin sodium; taurolidine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/heparin-taurolidine

> The FDA approved Defencath (heparin sodium; taurolidine), sponsored by CorMedix Inc. (CRMD), on November 15, 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Defencath (heparin sodium; taurolidine) FDA approved?

Yes. The FDA approved Defencath (heparin sodium; taurolidine), sponsored by CorMedix Inc. (CRMD), on November 15, 2023. FDA novel drug approvals: "Defencath | taurolidine, heparin | 11/15/2023 | To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheterDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/heparin-taurolidine)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/heparin-taurolidine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Defencath (heparin sodium; taurolidine) |
| Codes |  |
| Sponsor | CorMedix Inc. (CRMD) https://sec-api.dev/companies/crmd/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 26, 2021: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22214520_2023_Orig1s000OtherActionLtrs.pdf%22

### August 4, 2022: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22214520_2023_Orig1s000OtherActionLtrs.pdf%22

### November 15, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Defencath | taurolidine, heparin | 11/15/2023 | To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheterDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023
- openFDA Drugs@FDA: "NDA214520 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20231115, review_priority PRIORITY; sponsor_name CORMEDIX; product DEFENCATH (HEPARIN SODIUM; TAUROLIDINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214520%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/heparin-taurolidine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Defencath (heparin sodium; taurolidine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/heparin-taurolidine

```bibtex
@misc{secapidev_pdufa_heparin_taurolidine_20261116,
  title        = {Defencath (heparin sodium; taurolidine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/heparin-taurolidine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_heparin_taurolidine_20261116","title":"Defencath (heparin sodium; taurolidine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/heparin-taurolidine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
